Zacks Investment Research upgraded Prima BioMed Ltd (ADR) (NASDAQ:PBMD) to Hold in a statement released earlier today.
- Updated: October 1, 2016
Boasting a price of $0.91, Prima BioMed Ltd (ADR) (NASDAQ:PBMD) traded -0.11% lower on the day. With the last stock price close down -6.34% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Prima BioMed Ltd (ADR) has recorded a 50-day average of $0.87 and a two hundred day average of $0.95. Volume of trade was down over the average, with 24,581 shares of PBMD changing hands under the typical 90,259
Zacks Investment Research has upgraded Prima BioMed Ltd (ADR) (NASDAQ:PBMD) to Hold in a statement released on 09/29/2016.
With a total market value of $0, Prima BioMed Ltd (ADR) has with a one year low of $0.72 and a one year high of $1.54 .
A total of 4 equity analysts have released a research note on PBMD. One equity analyst rating the company a strong buy, two equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $6.03.
Brief Synopsis About Prima BioMed Ltd (ADR) (NASDAQ:PBMD)
Prima BioMed Ltd is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response. Its product, IMP321, is in clinical development for the treatment of a range of cancer indications, such as Metastatic Breast Cancer. IMP321 is in Phase IIb trials for Metastatic Breast Cancer and is being studied in Phase I for the treatment of Metastatic Melanoma. The Company is also focused on development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.